CoChat

Smoothened determines β-arrestin–mediated removal of the G protein–coupled receptor Gpr161 from the primary cilium

Open access

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Abstract

Dynamic changes in membrane protein composition of the primary cilium are central to development and homeostasis, but we know little about mechanisms regulating membrane protein flux. Stimulation of the sonic hedgehog (Shh) pathway in vertebrates results in accumulation and activation of the effector Smoothened within cilia and concomitant disappearance of a negative regulator, the orphan G protein–coupled receptor (GPCR), Gpr161. Here, we describe a two-step process determining removal of Gpr161 from cilia. The first step involves β-arrestin recruitment by the signaling competent receptor, which is facilitated by the GPCR kinase Grk2. An essential factor here is the ciliary trafficking and activation of Smoothened, which by increasing Gpr161–β-arrestin binding promotes Gpr161 removal, both during resting conditions and upon Shh pathway activation. The second step involves clathrin-mediated endocytosis, which functions outside of the ciliary compartment in coordinating Gpr161 removal. Mechanisms determining dynamic compartmentalization of Gpr161 in cilia define a new paradigm for down-regulation of GPCRs during developmental signaling from a specialized subcellular compartment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1083/jcb.201506132

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Ciliary loss of Gpr161 depends on its signaling activity and direct binding to β-arrestins. (A) Cartoon representing mutations in mouse Gpr161 (NP_001074595.1). CLS, ciliary localization signal (Mukhopadhyay et al., 2013); Δ, deletion of the C tail; CT, C terminus. (B and C) Confluent NIH 3T3 Flp-In cells stably expressing GFP-tagged WT and full-length Gpr161 mutant (V158E) were starved for 24 h, treated ±SAG (500 nM) for the last 4 h before fixing, and immunostained with anti-GFP (green) and anti–acetylated tubulin (AcTub; red) antibodies. Arrows and arrowheads indicate cilia positive and negative for Gpr161, respectively. All images were imported from ImageJ using similar parameters. Bar, 5 µm. Data represent mean ± SD from three independent experiments (C). *, P < 0.0001 with respect to untreated WT Gpr161. (D) Confluent WT, β-arrestin1 (Arrb1), β-arrestin2 (Arrb1), and β-arrestin1/2 double-knockout MEFs (Arrb1/2 ko) were serum starved for 48 h, treated ±Shh (300 ng/ml) for the indicated time points before fixation, and immunostained with anti-Gpr161 and anti–acetylated tubulin antibodies. Data represent mean ± SD from two independent experiments. *, P < 0.0001 with respect to untreated WT cells. Untreated whole-cell lysates immunoblotted with anti–β-arrestin (A1CT) antibody are shown to the right (arrowhead, nonspecific band). (E and F) T-REx 293 cells cotransfected with a constant amount of Rluc-tagged β-arrestin1/2 (donor) and increasing amounts of eYFP-tagged WT or indicated Gpr161 mutants (acceptor) were incubated with coelenterazine-h (5 µM) for 10 min. Readings were taken using the 475- and 535-nm emission filters simultaneously to compute net BRET ratios (Materials and methods). Total DNA transfected was maintained constant by transfecting empty vector. BRET50 values are shown above (Materials and methods). Data represent mean ± SD from three independent experiments. *, P = 0.01 with respect to only Gpr161/β-arrestin2 cotransfected cells. See also Fig. S1.
Figure 1. Ciliary loss of Gpr161 depends on its signaling activity and direct binding to β-arrestins. (A) Cartoon representing mutations in mouse Gpr161 (NP_001074595.1). CLS, ciliary localization signal (Mukhopadhyay et al., 2013); Δ, deletion of the C tail; CT, C terminus. (B and C) Confluent NIH 3T3 Flp-In cells stably expressing GFP-tagged WT and full-length Gpr161 mutant (V158E) were starved for 24 h, treated ±SAG (500 nM) for the last 4 h before fixing, and immunostained with anti-GFP (green) and anti–acetylated tubulin (AcTub; red) antibodies. Arrows and arrowheads indicate cilia positive and negative for Gpr161, respectively. All images were imported from ImageJ using similar parameters. Bar, 5 µm. Data represent mean ± SD from three independent experiments (C). *, P < 0.0001 with respect to untreated WT Gpr161. (D) Confluent WT, β-arrestin1 (Arrb1), β-arrestin2 (Arrb1), and β-arrestin1/2 double-knockout MEFs (Arrb1/2 ko) were serum starved for 48 h, treated ±Shh (300 ng/ml) for the indicated time points before fixation, and immunostained with anti-Gpr161 and anti–acetylated tubulin antibodies. Data represent mean ± SD from two independent experiments. *, P < 0.0001 with respect to untreated WT cells. Untreated whole-cell lysates immunoblotted with anti–β-arrestin (A1CT) antibody are shown to the right (arrowhead, nonspecific band). (E and F) T-REx 293 cells cotransfected with a constant amount of Rluc-tagged β-arrestin1/2 (donor) and increasing amounts of eYFP-tagged WT or indicated Gpr161 mutants (acceptor) were incubated with coelenterazine-h (5 µM) for 10 min. Readings were taken using the 475- and 535-nm emission filters simultaneously to compute net BRET ratios (Materials and methods). Total DNA transfected was maintained constant by transfecting empty vector. BRET50 values are shown above (Materials and methods). Data represent mean ± SD from three independent experiments. *, P = 0.01 with respect to only Gpr161/β-arrestin2 cotransfected cells. See also Fig. S1.CC BY-NC-SA · PubMed Central
Figure 2. Steady-state localization of Gpr161 in cilia is not controlled by Shh pathway activity. (A) Alternative models for Shh pathway activation-mediated Gpr161 loss from cilia: accumulation of Smo, removal of Ptch1, or downstream activation of pathway targets (left). Cartoon showing regulation of Smo trafficking to cilia by Smo antagonists (right; adapted partly from Rohatgi et al., 2009). Sufu−/− MEFs show increased Ptch1 levels in cilia (Fig. S2 E). (B and C) Confluent WT, Smo−/−, Ptch1−/− or Sufu−/− MEFs were serum starved for 48 h, treated ±500 nM SAG or 300 ng/ml octyl-Shh for the indicated time periods before fixation, and immunostained using anti-Gpr161 and anti–acetylated tubulin antibodies. Quantification of Gpr161-positive cilia from two independent experiments (mean ± SD). *, P < 0.05; #, P < 0.01 with respect to untreated WT cells in each panel. See also Fig. S2.
Figure 2. Steady-state localization of Gpr161 in cilia is not controlled by Shh pathway activity. (A) Alternative models for Shh pathway activation-mediated Gpr161 loss from cilia: accumulation of Smo, removal of Ptch1, or downstream activation of pathway targets (left). Cartoon showing regulation of Smo trafficking to cilia by Smo antagonists (right; adapted partly from Rohatgi et al., 2009). Sufu−/− MEFs show increased Ptch1 levels in cilia (Fig. S2 E). (B and C) Confluent WT, Smo−/−, Ptch1−/− or Sufu−/− MEFs were serum starved for 48 h, treated ±500 nM SAG or 300 ng/ml octyl-Shh for the indicated time periods before fixation, and immunostained using anti-Gpr161 and anti–acetylated tubulin antibodies. Quantification of Gpr161-positive cilia from two independent experiments (mean ± SD). *, P < 0.05; #, P < 0.01 with respect to untreated WT cells in each panel. See also Fig. S2.CC BY-NC-SA · PubMed Central
Figure 3. Presence of activated Smo in cilia determines steady-state levels of Gpr161. (A) Confluent WT MEFs were serum starved for 48 h, treated ±drugs for 24 h before fixation, and immunostained as in Figure 2 (B and C). Drugs used were as follows: 500 nM SAG, 1 µM KAAD-cyclopamine (KAAD), 1 µM GDC-0449 (GDC), 1 µM SANT1, and 5 µM cyclopamine (cyclo). Data represent mean ± SD from at least three independent experiments. **, P < 0.01; ***, P < 0.001 with respect to DMSO-treated cells. (B) Confluent Ptch1−/− MEFs were serum starved for 48 h, treated ±1 µM SANT1 for the last 24 h before fixation, and processed as in A. Quantification from two independent experiments (mean ± SD). **, P < 0.01 with respect to untreated cells. (C and D) Confluent WT and β-arrestin1/2 double-knockout MEFs (Arrb1/2 ko) were serum starved for 48 h, treated ±1 µM SAG in starvation media for 36 h before fixation, and immunostained using anti-Smo and anti–acetylated tubulin antibodies. Quantification from two independent experiments (mean ± SD) in C. Pixel intensities of Smo levels in cilia were determined by immunofluorescence (D); A.U., arbitrary units of fluorescence; n ≥ 43 each. *, P < 0.001 with respect to untreated cells in each background in C and D. (E) Confluent WT, Arrb1/2 double-knockout, or Smo knockout MEFs were starved for 18 h and further treated ± SAG/Shh for 30 h in starvation medium. Total RNA was isolated, and Gli1 expression levels were determined by quantitative real-time RT-PCR. Data represent mean ± SD from three experiments. *, P < 0.05; **, P < 0.01. (F) Confluent IMCD3 Flp-In cells were starved for 24 h. Next, cells were treated with 500 nM SAG for 3.5 h in starvation media, washed, and further treated ±1 µM KAAD-cyclopamine (KAAD) in starvation media before fixing. Cells were processed for Gpr161- and Smo-positive cilia by immunofluorescence. SAG>Veh and SAG>KAAD denotes pretreatment with SAG and subsequent treatment with vehicle (DMSO) or KAAD-cyclopamine, respectively. Data represent mean ± SD from three experiments for Gpr161 quantification and three fields from one experiment for Smo quantification. See also Fig. S3.
Figure 3. Presence of activated Smo in cilia determines steady-state levels of Gpr161. (A) Confluent WT MEFs were serum starved for 48 h, treated ±drugs for 24 h before fixation, and immunostained as in Figure 2 (B and C). Drugs used were as follows: 500 nM SAG, 1 µM KAAD-cyclopamine (KAAD), 1 µM GDC-0449 (GDC), 1 µM SANT1, and 5 µM cyclopamine (cyclo). Data represent mean ± SD from at least three independent experiments. **, P < 0.01; ***, P < 0.001 with respect to DMSO-treated cells. (B) Confluent Ptch1−/− MEFs were serum starved for 48 h, treated ±1 µM SANT1 for the last 24 h before fixation, and processed as in A. Quantification from two independent experiments (mean ± SD). **, P < 0.01 with respect to untreated cells. (C and D) Confluent WT and β-arrestin1/2 double-knockout MEFs (Arrb1/2 ko) were serum starved for 48 h, treated ±1 µM SAG in starvation media for 36 h before fixation, and immunostained using anti-Smo and anti–acetylated tubulin antibodies. Quantification from two independent experiments (mean ± SD) in C. Pixel intensities of Smo levels in cilia were determined by immunofluorescence (D); A.U., arbitrary units of fluorescence; n ≥ 43 each. *, P < 0.001 with respect to untreated cells in each background in C and D. (E) Confluent WT, Arrb1/2 double-knockout, or Smo knockout MEFs were starved for 18 h and further treated ± SAG/Shh for 30 h in starvation medium. Total RNA was isolated, and Gli1 expression levels were determined by quantitative real-time RT-PCR. Data represent mean ± SD from three experiments. *, P < 0.05; **, P < 0.01. (F) Confluent IMCD3 Flp-In cells were starved for 24 h. Next, cells were treated with 500 nM SAG for 3.5 h in starvation media, washed, and further treated ±1 µM KAAD-cyclopamine (KAAD) in starvation media before fixing. Cells were processed for Gpr161- and Smo-positive cilia by immunofluorescence. SAG>Veh and SAG>KAAD denotes pretreatment with SAG and subsequent treatment with vehicle (DMSO) or KAAD-cyclopamine, respectively. Data represent mean ± SD from three experiments for Gpr161 quantification and three fields from one experiment for Smo quantification. See also Fig. S3.CC BY-NC-SA · PubMed Central
Figure 4. Smo enhances recruitment of β-Arrestin to Gpr161. (A–D) T-REx 293 cells were cotransfected with a constant amount of Rluc–β-arrestin1/2 (donor) and increasing amounts of Gpr161-eYFP or Gpr161vl-eYFP (acceptor), ± untagged human Smo (0.1 µg/well of a six-well plate, 1×; 1 µg/well of a six-well plate, 10×; A and B) or mouse SmoWT-Myc, SmoA1-Myc or SmoA0-5-Myc (0.1 µg each/well of a six-well plate, 1× in C; 1 µg/well of a six-well plate, 10× in D). Cells were subjected to BRET analysis (Materials and methods). The titration curves are mean ± SEM from three independent experiments in all panels. *, P < 0.05; **, P < 0.01 for BRET50 values with respect to only Gpr161/β-arrestin2 cotransfected cells in each panel. Total DNA transfected was maintained constant by transfecting empty vector. (E) IMCD3 Flp-In cells were knocked out for Evc2 using CRISPR/Cas9 genome editing technology. Confluent cells were starved ±250 nM SAG for the last 24 h before fixing and immunostained to quantify for Gpr161-positive cilia. Data represent mean ± SD from two independent experiments. *, P < 0.05 with respect to DMSO-treated cells in each case. Merged images on right show Evc2-positive cilia as assessed by immunofluorescence; 80% (n = 485) in WT and 26% (n = 552) in Evc2 knockout. Bar, 5 µm (F) Confluent IMCD3 Flp-In cells were treated ±250 nM SAG ±800 ng/ml pertussis toxin for 24 h in starvation media after reaching confluence, fixed, and immunostained to quantify for Gpr161-positive cilia. Data represent mean ± SD from two independent experiments. *, P < 0.01 with respect to DMSO-treated cells in each case. See also Fig. S4.
Figure 4. Smo enhances recruitment of β-Arrestin to Gpr161. (A–D) T-REx 293 cells were cotransfected with a constant amount of Rluc–β-arrestin1/2 (donor) and increasing amounts of Gpr161-eYFP or Gpr161vl-eYFP (acceptor), ± untagged human Smo (0.1 µg/well of a six-well plate, 1×; 1 µg/well of a six-well plate, 10×; A and B) or mouse SmoWT-Myc, SmoA1-Myc or SmoA0-5-Myc (0.1 µg each/well of a six-well plate, 1× in C; 1 µg/well of a six-well plate, 10× in D). Cells were subjected to BRET analysis (Materials and methods). The titration curves are mean ± SEM from three independent experiments in all panels. *, P < 0.05; **, P < 0.01 for BRET50 values with respect to only Gpr161/β-arrestin2 cotransfected cells in each panel. Total DNA transfected was maintained constant by transfecting empty vector. (E) IMCD3 Flp-In cells were knocked out for Evc2 using CRISPR/Cas9 genome editing technology. Confluent cells were starved ±250 nM SAG for the last 24 h before fixing and immunostained to quantify for Gpr161-positive cilia. Data represent mean ± SD from two independent experiments. *, P < 0.05 with respect to DMSO-treated cells in each case. Merged images on right show Evc2-positive cilia as assessed by immunofluorescence; 80% (n = 485) in WT and 26% (n = 552) in Evc2 knockout. Bar, 5 µm (F) Confluent IMCD3 Flp-In cells were treated ±250 nM SAG ±800 ng/ml pertussis toxin for 24 h in starvation media after reaching confluence, fixed, and immunostained to quantify for Gpr161-positive cilia. Data represent mean ± SD from two independent experiments. *, P < 0.01 with respect to DMSO-treated cells in each case. See also Fig. S4.CC BY-NC-SA · PubMed Central
Figure 5. The GPCR kinase Grk2 determines removal of Gpr161 from cilia by inhibiting β-arrestin binding to the receptor. (A and B) IMCD3 Flp-In cells were reverse transfected with siRNA against indicated Grks for 72 h. Confluent cells were starved for the last 24 h ±250 nM SAG before fixing and processed for immunofluorescence using anti-Gpr161/Smo and anti–acetylated tubulin antibodies to quantify cilia positive for Gpr161/Smo by microscopy. Data represent mean ± SD from four independent experiments (A) and three separate fields from one experiment (B). *, P < 0.01; ***, P < 0.0001 with respect to SAG-treated control (ctrl) siRNA-treated cells (A); *, P < 0.0001 with respect to untreated cells in each condition (B). Inset in A shows the efficiency of Grk2 knockdown as assessed by immunoblotting. “% Remaining” siRNA (mean ± SD) for respective genes with respect to control siRNA-treated cells by quantitative real-time RT-PCR is shown at the bottom for Grk4-6. Arrows refer to Gpr161- or Smo-positive cilia, and arrowheads denote Smo-negative cilia. Bar, 5 µm. (C) GRK2 knockout (ko) lines in T-REx 293 cells were generated using CRISPR technology. Knockout lines were cotransfected with a constant amount of Rluc–β-arrestin2 (donor) and increasing amounts of eYFP-tagged Gpr161 WT or phosphosite mutant (acceptor) ±1 µg untagged human Smo per well of a six-well plate. The phosphosite mutant (C–E) constitutes mutating seven S/T to A in the C tail of full-length Gpr161 (376–401 aa; 376-ESFVQRQRTSRLFSISNRITDLGLSP-401). Cells were subjected to BRET analysis (Materials and methods) after pretreatment ±50 µM paroxetine (a selective GRK2 inhibitor) for 1 h (Thal et al., 2012; Homan et al., 2014). The titration curves are mean ± SD from two independent experiments. Efficiency of GRK2 knockouts as assessed by immunoblotting is shown to the top right. BRET assays performed in knockout line 2 are shown in Fig. S4 C. *, P < 0.05; **, P < 0.01 with respect to Rluc–β-arrestin2 binding to Gpr161-eYFP. (D and E) Confluent NIH 3T3 Flp-In cells stably expressing GFP-tagged Gpr161 phosphosite mutant were starved ±1 µM SAG, fixed, and processed for immunofluorescence and microscopy for Gpr161/Smo and acetylated tubulin. Bar, 5 µm. Data represent mean ± SD from two independent experiments (D) and three separate fields from one experiment (E). *, P < 0.001 with respect to untreated cells. See also Fig. S4.
Figure 5. The GPCR kinase Grk2 determines removal of Gpr161 from cilia by inhibiting β-arrestin binding to the receptor. (A and B) IMCD3 Flp-In cells were reverse transfected with siRNA against indicated Grks for 72 h. Confluent cells were starved for the last 24 h ±250 nM SAG before fixing and processed for immunofluorescence using anti-Gpr161/Smo and anti–acetylated tubulin antibodies to quantify cilia positive for Gpr161/Smo by microscopy. Data represent mean ± SD from four independent experiments (A) and three separate fields from one experiment (B). *, P < 0.01; ***, P < 0.0001 with respect to SAG-treated control (ctrl) siRNA-treated cells (A); *, P < 0.0001 with respect to untreated cells in each condition (B). Inset in A shows the efficiency of Grk2 knockdown as assessed by immunoblotting. “% Remaining” siRNA (mean ± SD) for respective genes with respect to control siRNA-treated cells by quantitative real-time RT-PCR is shown at the bottom for Grk4-6. Arrows refer to Gpr161- or Smo-positive cilia, and arrowheads denote Smo-negative cilia. Bar, 5 µm. (C) GRK2 knockout (ko) lines in T-REx 293 cells were generated using CRISPR technology. Knockout lines were cotransfected with a constant amount of Rluc–β-arrestin2 (donor) and increasing amounts of eYFP-tagged Gpr161 WT or phosphosite mutant (acceptor) ±1 µg untagged human Smo per well of a six-well plate. The phosphosite mutant (C–E) constitutes mutating seven S/T to A in the C tail of full-length Gpr161 (376–401 aa; 376-ESFVQRQRTSRLFSISNRITDLGLSP-401). Cells were subjected to BRET analysis (Materials and methods) after pretreatment ±50 µM paroxetine (a selective GRK2 inhibitor) for 1 h (Thal et al., 2012; Homan et al., 2014). The titration curves are mean ± SD from two independent experiments. Efficiency of GRK2 knockouts as assessed by immunoblotting is shown to the top right. BRET assays performed in knockout line 2 are shown in Fig. S4 C. *, P < 0.05; **, P < 0.01 with respect to Rluc–β-arrestin2 binding to Gpr161-eYFP. (D and E) Confluent NIH 3T3 Flp-In cells stably expressing GFP-tagged Gpr161 phosphosite mutant were starved ±1 µM SAG, fixed, and processed for immunofluorescence and microscopy for Gpr161/Smo and acetylated tubulin. Bar, 5 µm. Data represent mean ± SD from two independent experiments (D) and three separate fields from one experiment (E). *, P < 0.001 with respect to untreated cells. See also Fig. S4.CC BY-NC-SA · PubMed Central
Figure 6. Disappearance of Gpr161 from cilia is dependent on clathrin-mediated endocytosis. (A) Confluent NIH 3T3 Flp-In cells stably expressing GFP-tagged vl truncation of Gpr161 were starved for 24 h, treated ±500 nM SAG for the last 4 h before fixing and immunostained with anti-GFP (green) and anti–acetylated tubulin (AcTub; red) antibodies. All images were imported from ImageJ using similar parameters as in Fig. 1 B. Bar, 5 µm. Quantification from three independent experiments shown to the right (mean ± SD); *, P < 0.01 with respect to untreated GFP-tagged WT Gpr161. (B) IMCD3 Flp-In cells were infected with adenoviruses expressing dynamin 2K44A and tetracycline transactivator (tTA) in starvation media (±10 ng/ml doxycycline [Dox]) and treated ±250 nM SAG for the last 4.5 h before fixing (top left). Simultaneous treatment with 50 µg/ml transferrin-Alexa647 (Tf-Alexa647) for the last 30 min was used to estimate for dynamin inhibition. Fixed cells were processed for immunofluorescence for Gpr161 and acetylated tubulin. Overall efficiency of dynamin2 overexpression was also assessed by immunoblotting (left). Data represent mean ± SD from three independent experiments. ***, P < 0.0001; NS, not significant; N, total number of cells counted. (C) IMCD3 Flp-In cells were transfected with siRNAs against clathrin heavy chain (Chc) for 72 h. Confluent cells were starved for the last 24 h, treated with 30 ng/ml Shh for the indicated time periods before fixing, and processed for immunofluorescence for Gpr161 (green) and acetylated tubulin (red). Data represent mean ± SD from two independent experiments. *, P < 0.01; **, P < 0.001; ***, P < 0.0001 with respect to untreated control siRNA-treated cells. Inset shows the efficiency of Chc knockdown as assessed by immunoblotting. Representative images after 2 h of Shh treatment are shown to the left. Arrows indicate cilia positive for Gpr161 (A and C). Bar, 5 µm. See also Fig. S5.
Figure 6. Disappearance of Gpr161 from cilia is dependent on clathrin-mediated endocytosis. (A) Confluent NIH 3T3 Flp-In cells stably expressing GFP-tagged vl truncation of Gpr161 were starved for 24 h, treated ±500 nM SAG for the last 4 h before fixing and immunostained with anti-GFP (green) and anti–acetylated tubulin (AcTub; red) antibodies. All images were imported from ImageJ using similar parameters as in Fig. 1 B. Bar, 5 µm. Quantification from three independent experiments shown to the right (mean ± SD); *, P < 0.01 with respect to untreated GFP-tagged WT Gpr161. (B) IMCD3 Flp-In cells were infected with adenoviruses expressing dynamin 2K44A and tetracycline transactivator (tTA) in starvation media (±10 ng/ml doxycycline [Dox]) and treated ±250 nM SAG for the last 4.5 h before fixing (top left). Simultaneous treatment with 50 µg/ml transferrin-Alexa647 (Tf-Alexa647) for the last 30 min was used to estimate for dynamin inhibition. Fixed cells were processed for immunofluorescence for Gpr161 and acetylated tubulin. Overall efficiency of dynamin2 overexpression was also assessed by immunoblotting (left). Data represent mean ± SD from three independent experiments. ***, P < 0.0001; NS, not significant; N, total number of cells counted. (C) IMCD3 Flp-In cells were transfected with siRNAs against clathrin heavy chain (Chc) for 72 h. Confluent cells were starved for the last 24 h, treated with 30 ng/ml Shh for the indicated time periods before fixing, and processed for immunofluorescence for Gpr161 (green) and acetylated tubulin (red). Data represent mean ± SD from two independent experiments. *, P < 0.01; **, P < 0.001; ***, P < 0.0001 with respect to untreated control siRNA-treated cells. Inset shows the efficiency of Chc knockdown as assessed by immunoblotting. Representative images after 2 h of Shh treatment are shown to the left. Arrows indicate cilia positive for Gpr161 (A and C). Bar, 5 µm. See also Fig. S5.CC BY-NC-SA · PubMed Central
Figure 7. Mechanism of Gpr161 loss from cilia. Model for Gpr161 loss from cilia (Discussion). Abbreviations: BB, basal body; CP, ciliary pocket; CM, ciliary membrane; Gpr161A, signaling-competent Gpr161; Gpr161I, inactive Gpr161; PM, plasma membrane; SmoI, inactive Smo; SmoA, Smo in active conformation; TZ, transition zone.
Figure 7. Mechanism of Gpr161 loss from cilia. Model for Gpr161 loss from cilia (Discussion). Abbreviations: BB, basal body; CP, ciliary pocket; CM, ciliary membrane; Gpr161A, signaling-competent Gpr161; Gpr161I, inactive Gpr161; PM, plasma membrane; SmoI, inactive Smo; SmoA, Smo in active conformation; TZ, transition zone.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 88 references

Cited by

See all 141

Metadata

Authors
Pal, K., Hwang, S.-H., Somatilaka, B., Badgandi, H., Jackson, P. K., DeFea, K., & Mukhopadhyay, S.
Affiliations
  • The University of Texas Southwestern Medical Center (US)
  • Stanford Medicine (US)
  • University of California, Riverside (US)
Corresponding author
Mukhopadhyay, Saikat
Venue
Journal of Cell Biology
Published
2016-03-21
Volume
212
Issue
7
Pages
861-875
ISSN
  • 0021-9525 (ISSN-L)
  • 1540-8140
OpenAlex
W2310131378
Cited by
141
References
88
Citations by year
2026: 11 · 2025: 14 · 2024: 15 · 2023: 11 · 2022: 6 · 2021: 21 · 2020: 16 · 2019: 14 · 2018: 12 · 2017: 10 · 2016: 11
FWCI
12.64
Type
journal article
Language
en
Open access
Licence
cc-by-nc-sa
Locations
  • The Journal of Cell Biology (publishedVersion, cc-by-nc-sa)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Cancer Prevention Research Institute of Texas (R1220)
  • National Institutes of Health (1R01GM113023-01)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Hedgehog Signaling Pathway Studies
Keywords
Smoothened, GPR161, beta-arrestin, primary cilia, Sonic hedgehog signaling, GRK2, GPCR kinases, clathrin-mediated endocytosis, receptor internalization
MeSH terms
beta-Arrestins, Smoothened Receptor, Animals, Cilia, Endocytosis, Fibroblasts, Humans, Mutation, Protein Binding, Time Factors, Transfection, Biosensing Techniques, Signal Transduction, Down-Regulation, Arrestins, Protein Transport, RNA Interference, NIH 3T3 Cells, Receptors, G-Protein-Coupled, Mice, Hedgehog Proteins, G-Protein-Coupled Receptor Kinase 2, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Smoothened determines β-arrestin–mediated removal of the G protein–coupled receptor Gpr161 from the primary cilium. https://app.cochat.ai/papers/10.1083/jcb.201506132
The paper
Pal, K., Hwang, S.-H., Somatilaka, B., Badgandi, H., Jackson, P. K., DeFea, K., & Mukhopadhyay, S. (2016). Smoothened determines β-arrestin–mediated removal of the G protein–coupled receptor Gpr161 from the primary cilium. Journal of Cell Biology. https://doi.org/10.1083/jcb.201506132

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.